OTR-011

OTR-011 is a preclinical-stage therapeutic candidate developed by OTR Therapeutics for the treatment of oncology. It is based on the company's proprietary ReGeneraTing Agent (RGTA®) technology, which involves the development of synthetic polymers engineered to mimic the structural and functional properties of heparan sulfates in the extracellular matrix (ECM). These agents are designed to stabilize and protect signaling proteins, such as growth factors and cytokines, from proteolytic degradation, thereby modulating signaling pathways involved in tissue repair and tumor progression. While the specific molecular target of OTR-011 remains undisclosed by the sponsor, the drug is intended to alter the tumor microenvironment to inhibit cancer growth and promote tissue homeostasis.